Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P23786
UPID:
CPT2_HUMAN
Alternative names:
Carnitine palmitoyltransferase II
Alternative UPACC:
P23786; B2R6S0; Q5SW68; Q9BQ26
Background:
Carnitine O-palmitoyltransferase 2, mitochondrial, also known as Carnitine palmitoyltransferase II, plays a crucial role in the intramitochondrial synthesis of acylcarnitines from accumulated acyl-CoA metabolites. It is pivotal for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation, with activity on medium and long-chain acyl-CoA esters.
Therapeutic significance:
Carnitine palmitoyltransferase II deficiency manifests in various forms, including myopathic, infantile, and lethal neonatal types, alongside susceptibility to infection-induced encephalopathy. Understanding its function could lead to breakthroughs in treating these metabolic disorders.